A Design of Experiments for Tablet Compression - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Design of Experiments for Tablet Compression
The author prepared and analyzed a detailed design of experiments for the manufacture of a simple tablet formulation. The aim was to test whether tablet hardness and weight could be controlled during the compression process by adjusting certain machine parameters.


Pharmaceutical Technology
Volume 35, Issue 9

Analysis of experimental design


Figure 1: Half-normal plot of tablet hardness.
Hardness response. Two responses, tablet hardness and tablet weight, were measured throughout the set of experiments. Each measure response was analyzed individually. Using Design-Expert software, a half-normal plot of the experimental data results was constructed from the original screening results. The half-normal plot for the tablet hardness is shown in Figure 1. Only the significant factors are identified in the half-normal plot. After the sample tablets were pulled from the rotary tablet press, the tablets were left stationary for 2 min before being tested, according to the standard protocol, as previously described. During a formal campaign, the finished batch may be held for at least 24 h before being sampled and tested again. The purpose of the delay is to ensure that the tablets did not rebound because of the compressed material's elasticity. Elastic tablets tend to expand after compression, thus causing a decrease in measured tablet hardness.


Table V: Analysis of variance for augmented central composite design model according to tablet hardness.
The half-normal plot indicates that factors A, C, D, and E, and interactions CD and CE significantly affected the hardness response. The analysis of variance shown in Table V supports the plot in Figure 1.

In the next equation, R 2 is 0.9881, adjusted R 2 is 0.9842, and adequate precision is 56.625. The R 2 of 0.9881 is in reasonable agreement with the adjusted R 2 of 0.9842. The adequate precision ratio of 56.625 indicates an adequate signal, so the following model, in terms of coded factors, can be used to establish the design space:





Figure 2: Normal plot of residuals for hardness.
The 95% confidence intervals for all significant factors were verified to exclude zero, which supports the determination that all identified terms in the model equation influence the response. A normal plot of residuals was constructed to determine whether residuals followed a normal distribution (see Figure 2). A plot of residuals versus predicted was constructed to discover convincing trends to the residuals or suspected outliers in the data (see Figure 3). All data points are equally distributed and are within two standard deviations from the mean with two exceptions: one high point is 2.206 standard devations, and one low point is –2.312 standard deviations. The two data points that lie beyond two standard deviations of the mean could be investigated, and these experiments may warrant being rerun to confirm the data response. The data showed no potential outliers.


Figure 3: Residuals versus predicted plot for hardness.


Appendix Figure 1: Hardness interaction plot for precompression and main compression.
Plots were generated for the interactions of CD and CE. These plots are included in the appendix of supporting figures. The 3D-contour CD interaction plot is shaped like a spade because of the data collected during the centerpoint experimental runs. The interaction plot shows that tablet hardness increased as main compression and precompression heights were reduced (see Appendix Figures 1 and 2). This makes logical sense because when the compression rollers are pulled close together, high compression forces are imposed on the tablet, thus resulting in hard tablets. Both 3D plots and standard interaction plots support this analysis.


Appendix Figure 2: Hardness 3D interaction plot for precompression and main compression.


Appendix Figure 3: Hardness interaction plot for precompression and fill-cam height.
The 3D contour CE interaction plot shows a response similar in shape to that of the CD interaction plot, but the shape is more easily interpreted as a channel (i.e., an inverted ridge with a slope that has not yet reached its minimum). The CE interaction plot (see Appendix Figures 3 and 4) indicates an increase in hardness when the fill-cam height (i.e., factor E) is low or high and the precompression roller height is reduced (thus increasing compression force), as would be expected. The tablet weight responded linearly as the fill-cam height (i.e., the weight-adjustment ramp) changed.


Appendix Figure 4: Hardness 3D interaction plot for precompression and fill-cam height.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here